spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare News Roundup: Neurology

 HSMN NewsFeed - 23 Nov 2020
Rapid Medical Expands Comaneci(TM) CE Mark Indication to Include Vasospasm Treatment
Devices Interventional Neurology Regulatory
 HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Nov 2020
NeurodigitX Launches First Digital Inflammatory Biomarker Platform to Support COVID-19 Pandemic Exit Strategy
Devices Neurology Monitoring Product Launch
 HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology
 HSMN NewsFeed - 3 Nov 2020
Salvia BioElectronics receives FDA Breakthrough Device Designation for innovative neurostimulation solution
Devices Neurology FDA
 HSMN NewsFeed - 2 Nov 2020
Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 29 Oct 2020
Medtronic Expands ENT Portfolio with FDA Clearance of NIM Vital(TM) Next Generation Intraoperative Nerve Monitoring System and Acquisiton of Ai Biomed Corp.
Devices Neurology FDA Mergers & Acquisitions
 HSMN NewsFeed - 19 Oct 2020
Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO
Diagnostics Neurology Personnel
 HSMN NewsFeed - 16 Oct 2020
Enterin Announces Appointment of New CEO
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 9 Oct 2020
Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Oct 2020
REYVOW(R) (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study
Biopharmaceuticals Neurology
Older Neurology stories   Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.